PerfuseCell Cronus A/S: Financial statements 2023
CVR: 31606810
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
PerfuseCell Cronus A/S (CVR 31606810) has filed annual accounts for 2023. In 2023, the company reported revenue of DKK 711,014 and a net result of DKK 171,478 compared with DKK 89,285 the year before. That is an increase of 29.4% compared with the year before. The profit margin was 24.1%. Equity in the 2023 report amounted to DKK 1,044,646. The solvency ratio was 100%.
- Revenue
- DKK 711,014
- Gross Profit
- DKK 149,857
- Profit/Loss
- DKK 171,478
- Equity
- DKK 1,044,646
- Total Assets
- DKK 1,044,646
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 711 t. | 150 t. | 171 t. | 1 mio. | - |
| 2022 | 550 t. | 131 t. | 89 t. | 873 t. | - |
| 2021 | 150 t. | 34 t. | 34 t. | 784 t. | - |
| 2020 | 385 t. | 87 t. | 87 t. | 750 t. | - |
| 2019 | 220 t. | 172 t. | 172 t. | 663 t. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
PerfuseCell Cronus A/S has published its annual report for 2022. Revenue came to DKK 549,675, and the net result was DKK 89,285.
About PerfuseCell Cronus A/S
PerfuseCell Cronus A/S is a Danish company of the type Aktieselskab based in Herlev, founded in 2008. The company is registered under the industry Fremstilling af medicinske og dentale instrumenter samt udstyr hertil. The company was previously named PerfuseCell A/S and PumpCell A/S. The management consists of Per Stobbe. The board consists of August Kisling Stobbe, Flemming Petersen and Per Stobbe. The company is owned by Stobbe GmbH. In 2025, the company reported a gross profit of DKK 20,467 and a net result of DKK 23,973 compared with DKK 2,216 the year before. Equity in the 2025 report amounted to DKK 1,070,836.